Bryan A. Irving Ph.D.
Dr. Irving is responsible for 3T’s scientific strategy and direction and chairs 3T’s Scientific Advisory Board. He is a highly respected scientist with more than 30 years of experience working across diverse disciplines of R&D to deliver innovative medicines. Before joining 3T, Dr. Irving was senior advisor at Frazier Life Sciences and prior to this role he was CSO at Amunix Pharmaceuticals until its acquisition by Sanofi. Previously, Dr. Irving was executive vice president and CSO of Five Prime Therapeutics (acquired by Amgen) and vice president, Cancer Immunology at CytomX. Following post-doctoral work at Harvard and University of California, San Francisco, Dr. Irving began his industry career at Genentech where for 12 years his work focused on biologics’ drug discovery and development in both areas of inflammation and immune oncology. Among his most notable contributions at Genentech was serving as key inventor and research leader of the PD-L1 immunotherapy TECENTRIQ® (atezolizumab). Dr. Irving received his Ph.D. in immunology from the University of California, San Francisco.
